Muftuler F.Z.B.Demir I.Ünak P.Içhedef Ç.Kilçar A.Y.2019-10-272019-10-2720110033-82300033-8230https://doi.org/10.1524/ract.2011.1827https://hdl.handle.net/11454/26901An antitumor agent paclitaxel (PAC) has been proved to be efficient in the treatment of breast and ovarian cancer. Glucuronic acid-derived paclitaxel compound (paclitaxel-glucuronide (PAC-G)) was enzymatically synthesized using microsome preparate separated from rat livers. The biodistribution mechanism of PAC-G in healthy female Albino Wistar rats has been investigated. The expected structure is confirmed according to LC/MS results, and the possible attachment is to C2-hydroxyl group. PAC-G was labeled with 99mTc and the radiochemical yield of radiolabeled compound (99mTc-PAC-G) was 98.00 ±2.74% (n = 9). The range of the breast/blood and breast/muscle ratios is approximately between 3 and 35 in 240 min. All these experimental studies indicate that 99mTc-PAC-G may potentially be used in breast tissue as an imaging agent. © by Oldenbourg Wissenschaftsverlag, München.en10.1524/ract.2011.1827info:eu-repo/semantics/closedAccessBioavailability of 99mTc-paclitaxel-glucuronide ( 99mTc-PAC-G)Article995301306Q3